Research. Advocacy. Support.
We advance ovarian cancer research while supporting women and their families.
Know Your Risks
About 20 to 25 percent of women diagnosed with ovarian cancer have a hereditary tendency to develop the disease.
(April 26, 2017) A study recently published in Cancer evaluates the effect that cediranib, a drugs that stops the growth of new blood vessels, has on a patient’s quality of life (QOL) when used as maintenance therapy. Previous studies have shown that, for patients with relapsed epithelial ovarian cancer, cediranib used as maintenance therapy can… More
(April 25, 2017) Researchers from Roswell Park Cancer Institute used data from 15 different studies that were part of the Ovarian Cancer Association Consortium, partially funded by OCRFA, to examine the relationship between epithelial ovarian cancer and hypertension, heart disease, diabetes, and the medications associated with those diseases. After reviewing over 7,600 cases, it was… More
A study published in Nature Genetics has identified nine new susceptibility loci, or disease-associated alleles, for different epithelial ovarian cancer (EOC) histotypes and three susceptibility loci within BRCA1 and 2 mutation carriers with EOC. Researchers, including former OCRFA grantee and current OCRFA Scientific Advisory Committee Member Andrew Berchuck, looked at data from 25,509 EOC cases… More
Join us for an evening of laugh-out-loud stand up performances, a raucous live auction, and cocktail...May 15 @ 6:00 pm - 8:30 pm EDT
This is truly a can’t miss event—join us in Chicago for a weekend of hope, inspirat...July 7 @ 8:00 am - July 9 @ 5:00 pm EDT
OCRFA’s Super Saturday is a daylong shopping event that brings top luxury name brands in high ...July 29 @ 8:00 am - 5:00 pm EDT